Application of a Fracture Risk Algorithm to Men Treated With Androgen Deprivation Therapy for Prostate Cancer
- 30 June 2010
- journal article
- Published by Ovid Technologies (Wolters Kluwer Health) in Journal of Urology
- Vol. 183 (6), 2200-2205
- https://doi.org/10.1016/j.juro.2010.02.022
Abstract
Osteoporosis causes morbidity and mortality in men. The National Osteoporosis Foundation recommends fracture risk assessment with the online WHO/FRAX® tool. Although androgen deprivation therapy for prostate cancer increases fracture risk, there is limited information about which men require preventative drug therapy. We applied the WHO/FRAX tool to men treated with androgen deprivation therapy for prostate cancer. Information was collected from a practice cohort of men treated with gonadotropin-releasing hormone agonists, and included age, height, weight, history of gonadotropin-releasing hormone agonist treatment, dual energy x-ray absorptiometry results, prior bone targeted therapy and clinical risk factors for fracture. Subjects were evaluated with the WHO/FRAX algorithm (http://www.shef.ac.uk/FRAX/). A total of 363 men treated with androgen deprivation therapy (median age 72 years) were evaluated. By the FRAX algorithm with clinical information (no dual energy x-ray absorptiometry data) the 3% hip fracture risk threshold for treatment was exceeded by 51.2% of the men (median risk 3.1%). When subjects were grouped by age the treatment threshold was reached by 3.3% of those younger than 70 years, 76.6% of those 70 to 79 years old and by 98.8% of those 80 years old or older. Using FRAX with bone mineral density data in the 93 patients who underwent bone mineral density testing the median 10-year hip fracture risk was 0.9% and the treatment threshold was exceeded by 15% of these subjects. In this cohort of men receiving androgen deprivation therapy the prevalence of risk sufficient to necessitate drug therapy was high and was strongly influenced by age. The WHO/FRAX algorithm identifies a greater proportion of men for treatment than the traditional threshold of T score −2.5 or less.Keywords
This publication has 33 references indexed in Scilit:
- FRAX™ and the assessment of fracture probability in men and women from the UKOsteoporosis International, 2008
- Risk of Clinical Fractures After Gonadotropin-Releasing Hormone Agonist Therapy for Prostate CancerJournal of Urology, 2006
- Gonadotropin-Releasing Hormone Agonists and Fracture Risk: A Claims-Based Cohort Study of Men With Nonmetastatic Prostate CancerJournal of Clinical Oncology, 2005
- A family history of fracture and fracture risk: a meta-analysisBone, 2004
- A meta-analysis of previous fracture and subsequent fracture riskBone, 2004
- Zoledronic Acid Versus Placebo in the Treatment of Skeletal Metastases in Patients With Lung Cancer and Other Solid Tumors: A Phase III, Double-Blind, Randomized Trial—The Zoledronic Acid Lung Cancer and Other Solid Tumors Study GroupJournal of Clinical Oncology, 2003
- Changes in Bone Mineral Density, Lean Body Mass and Fat Content as Measured by Dual Energy X-Ray Absorptiometry in Patients With Prostate Cancer Without Apparent Bone Metastases Given Androgen Deprivation TherapyJournal of Urology, 2002
- Changes in Body Composition during Androgen Deprivation Therapy for Prostate CancerJournal of Clinical Endocrinology & Metabolism, 2002
- Osteoporosis in MenJournal of Clinical Endocrinology & Metabolism, 1999
- BONE MINERAL DENSITY IN MEN TREATED WITH SYNTHETIC GONADOTROPIN-RELEASING HORMONE AGONISTS FOR PROSTATIC CARCINOMAJournal of Urology, 1999